Exelixis, Inc. (NASDAQ:EXEL) Position Increased by State of Wyoming

State of Wyoming lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 357.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,360 shares of the biotechnology company's stock after purchasing an additional 9,658 shares during the period. State of Wyoming's holdings in Exelixis were worth $412,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in EXEL. Coppell Advisory Solutions LLC acquired a new position in Exelixis during the fourth quarter worth about $25,000. Colonial Trust Co SC raised its position in Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares during the last quarter. Principal Securities Inc. raised its position in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 373 shares during the last quarter. Kestra Investment Management LLC acquired a new position in Exelixis during the fourth quarter worth about $39,000. Finally, UMB Bank n.a. raised its position in Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 553 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Insiders Place Their Bets

In other news, CFO Christopher J. Senner sold 29,314 shares of the business's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.14, for a total transaction of $1,059,407.96. Following the transaction, the chief financial officer now directly owns 779,607 shares of the company's stock, valued at approximately $28,174,996.98. The trade was a 3.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 126,383 shares of the business's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the transaction, the executive vice president now directly owns 446,459 shares in the company, valued at approximately $21,412,173.64. The trade was a 22.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 559,873 shares of company stock worth $24,646,347 over the last ninety days. 2.82% of the stock is owned by company insiders.

Exelixis Trading Down 1.1%

EXEL traded down $0.47 during trading on Friday, hitting $42.39. 2,939,995 shares of the company's stock were exchanged, compared to its average volume of 2,300,007. Exelixis, Inc. has a 1 year low of $20.14 and a 1 year high of $48.85. The stock has a 50 day moving average price of $37.91 and a 200 day moving average price of $36.14. The firm has a market cap of $11.56 billion, a P/E ratio of 23.95, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Exelixis from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 15th. Barclays lifted their target price on shares of Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Exelixis in a research report on Thursday, March 27th. Citigroup lifted their price target on shares of Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Finally, Guggenheim set a $45.00 price target on shares of Exelixis and gave the stock a "buy" rating in a report on Thursday, May 15th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Exelixis has an average rating of "Moderate Buy" and an average price target of $38.94.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.